(±)-Enitociclib
Product Sizes
50 mg
HY-103019A-50MG
10 mg
HY-103019A-10MG
5 mg
HY-103019A-5MG
100 mg
HY-103019A-100MG
10mM/1mL
HY-103019A-10MM
About this Product
- SKU:
- HY-103019A
- Additional Names:
- (±)-BAY-1251152; (±)-VIP152
- CAS Number:
- 1610358-53-6
- Extra Details:
- (±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II; thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells; and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003); and can be used in the research of hematological malignancies[1][2].
- Molecular Weight:
- 404.43
- Purity:
- 99.23
- References:
- [1]Frigault MM, et al. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023 Nov 9;3(11):2268-2279.|[2]Tran S, et al. Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma[J]. Blood Neoplasia, 2025, 2(1): 100050.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Cell Cycle/DNA Damage
